Community protocols on TRT describe: 5-10 mg subcutaneous, 3-5x per week Dosing on training days for synergy with exercise 8-12 week cycles Monitoring fasting glucose and insulin-sensitivity markers For the full protocol, see our MOTS-c dosing guide and MOTS-c results timeline
The STEP programme clinical trial further looked at the benefits of semaglutide such as delayed gastric emptying in women with polycystic ovary syndrome (PCOS), which is the most common endocrine disorder in women of reproductive age, and obesity, as well as healthier eating habits, better portion sizes and overall less food cravings
Investigators have assessed multiple administration routes, including subcutaneous, intramuscular, intravenous, oral, and topical delivery in experimental models
Fragment (176191) is a modified C-terminal fragment of human growth hormone, while CJC-1295 (No DAC) is a growth hormonereleasing hormone (GHRH) analog and Ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist
